Ann: Security Class Reinstatement to Quotation- OPTOB, page-457

Pretty much my thinking. Essentially, the physiological pathway of treatment today appears to involve the downregulation/inhibition of VEGF-A ("over" growth factor). However, the mechanism by which this occurs, particularly with Eylea and Lucentis, can, over months, lead to the upregulation of VEGF-C/D ("over" growth factor) in many/most patients. It appears that Sozinibercept clamps this upregulatory effect of C growth factor, and thus expect Shore and Coast to be highly correlated, with both either succeeding or failing together. That said, believe we are highly likely to see a reproduction or improvement on the P2B results.